Loading…

Loading grant details…

Active HORIZON European Commission

The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents

€3.3M EUR

Funder European Commission
Recipient Organization Nimble Diagnostics Sl
Country Spain
Start Date Feb 01, 2024
End Date Jan 31, 2026
Duration 730 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101145249
Grant Description

At NIMBLE Diagnostics we are developing a first-in-class microwave-based medical device for the non-invasive and non-ionizing monitoring of patients with implanted stents.Stents are one of the most implanted devices worldwide and are used to re-open blocked arteries and restore the correct flow of blood or other fluids.

They are especially useful to prevent heart attacks or to treat their lasting symptoms, but, after implantation, become blocked or damaged in 30% of cases.

Symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence of serious complications, including strokes, heart attacks or sudden death.

Diagnosis of malfunctioning stents is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery.

This complex, costly and invasive procedure is not appropriate for ongoing monitoring, which is why the standard of care only reacts when patients already have potentially life-threatening symptoms.The NIMBLE System can read the electromagnetic signature of any stent non-invasively in less than 5 seconds and can be used to provide information on stent status and malfunction during regular clinical visits.

Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of therapy, shifting from reactive to proactive care.Our technology is currently at TRL5/6, with an MVP that has shown excellent results in pre-clinical validations.

We have also started the first-in-human testing in a pilot study of 30 patients that will finish early 2024.The EIC Accelerator program will allow us to bridge the biggest risk of our project by performing the regulatory clinical trial to obtain the CE mark, as well as support us to create and access a multi-billion blue ocean market opportunity.

This will allow us to establish NIMBLE as a European leader in the future of implant diagnostics and aid millions of patients worldwide.

All Grantees

Nimble Diagnostics Sl

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant